Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support

Table 3

Independent risk factors for progression-free survival (PFS) and overall survival (OS) at diagnosis of metastasis.

	𝑛	PFS		OS
		HR (95%CI)		HR (95% CI)
		HR (95% CI)	𝑃	HR (95% CI)	𝑃
BMI
<30	72	1		1
≥30	23	2.23 (1.28, 3.88)	0.005	1.82 (1.03, 3.23)	0.04
Stage at diagnosis
Stage I	21	1		1
Stage II	43	5.09 (2.55, 10.16)	<0.001	2.87 (1.53, 5.4)	0.001
Stage III	23	3.58 (1.61, 7.94)	0.002	2.61 (1.22, 5.58)	0.01
Stage IV	8	6.88 (2.54, 18.6)	<0.001	3.88 (1.52, 9.9)	0.04
Site of metastasis
Local	16	1		1
Nodal	14	1.37 (0.59, 3.2)	0.47	1.38 (0.6, 3.16)	0.45
Bone	28	1.79 (0.84, 3.82)	0.13	1.60 (0.76, 3.38)	0.22
Visceral	37	4.45 (2.12, 9.37)	<0.001	2.54 (1.25, 5.15)	0.01